地榆升白片预防老年NSCLC患者术后辅助化疗中骨髓抑制.docVIP

地榆升白片预防老年NSCLC患者术后辅助化疗中骨髓抑制 　【摘要】 　目的 观察评价地榆升白片（强力升白片）在预防老年非小细胞肺癌（NSCLC）患者术后辅助化疗中对骨髓抑制的影响。方法 78例手术切除的NSCLC患者，随机分成治疗组（强力升白片+化疗）和对照组（利血生+化疗），化疗前、化疗结束后及化疗结束后1、2周查外周血白细胞水平。结果 化疗结束后，治疗组及对照组骨髓抑制发生率分别为20.00%和27.63%，两组比较无统计学差异（Pgt;0.05）；化疗结束后1、2周两组骨髓抑制发生率分别为22.50%、33.55%和9.38%、17.11%，两组比较均有显著性差异（Plt;0.05）。结论 地榆升白片升高白细胞的作用显著，可有效预防并减轻老年非小细胞肺癌患者术后辅助化疗中的骨髓抑制，明显提高患者的化疗耐受性。 【关键词】 地榆升白片　非小细胞肺癌　化疗 　　Clinical Study on Diyushengbai Tablet to Prevent Blood Cell Reduction of Postoperative NSCLC Elder Patients with Adjuvant Chemotherapy WANG Wei,ZANG Qi,SONG Xiaoming Department of Thoracic Surgery,Qianfoshan Hospital of Shandong Province,Ji’nan 250014,ChinaAbstract：Objective The objective of this study is to evaluate the effect of diyushengbai tablet on the blood cell count of postoperative NSCLC patients with adjuvant chemotherapy.Methods The patients were randomized into two groups: the test group consisted of 40 patients treated with a combination of diyushengbai tablet and MVP chemotherapy，the control group comprised 38 patients treated with lixuesheng tablet and MVP chemotherapy.The patients were evaluated to white blood cell before and 1,2 weeks after treatment.Results The rate of bone marrow depression in the end of chemotherapy in test group and control group were 20.00% and 27.63% respectively.No difference was found between two groups(Pgt;0.05).1 and 2 weeks after chemotherapy,the rate of depression in two groups were 22.50%、33.55% and 9.38%、17.11% respectively.There was a significant difference between them(Plt;0.05).Conclusion Diyushengbai tablet was effective to prevent the depression of bone marrow and raise WBC of the postoperative NSCLC patients treated with the adjuvant chemotherapy. Key words：Diyushengbai tablet;Nonsmall cell lung cancer;Chemotherapy 　　辅助化疗是非小细胞肺癌患者术后治疗的主要方法，但化疗药物造成的骨髓抑制，尤其白细胞水平的明显降低常常使病人中断或延期化疗，使患者的治疗效果大受影响。rhGGSF重组基因粒细胞集落刺激因子刺激骨髓造血虽然效果良好，但其价格昂贵，临床应用受到很大限制。我们应用升白细胞药物地榆升白片（地奥集团天府药业生产），预防老年非小细胞肺癌患者术后化疗所导致的白细胞降低取得了良好效果，总结报告如下。 1研究方法 1.1随机分组方法 选择